KRYS logo

KRYS
Krystal Biotech Inc

1,749
Mkt Cap
$8.46B
Volume
75,284.00
52W High
$295.98
52W Low
$122.80
PE Ratio
43.77
KRYS Fundamentals
Price
$285.86
Prev Close
$291.79
Open
$290.82
50D MA
$230.34
Beta
0.94
Avg. Volume
304,086.68
EPS (Annual)
$3.00
P/B
7.43
Rev/Employee
$1.06M
News
all
press releases
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.
Zacks·1d ago
News Placeholder
More News
News Placeholder
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
Zacks·1d ago
News Placeholder
5 Stocks With Recent Price Strength to Maximize Your Gains
ISSC, AUGO, OWLT, KRYS and IDN are among a select group of stocks showing strong recent price momentum.
Zacks·1d ago
News Placeholder
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Zacks·2d ago
News Placeholder
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price
Citigroup lifted their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·3d ago
News Placeholder
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
Zacks·3d ago
News Placeholder
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Analysts
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been given an average recommendation of "Buy" by the eleven analysts that are currently covering the stock, MarketBeat.com reports. One...
MarketBeat·4d ago
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $306.00 at TD Cowen
TD Cowen boosted their price objective on Krystal Biotech from $202.00 to $306.00 and gave the company a "buy" rating in a research note on Friday...
MarketBeat·6d ago
News Placeholder
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks·6d ago
News Placeholder
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
Zacks·7d ago
<
1
2
...
>

Latest KRYS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.